According to filings with the U.S. Securities and Exchange Commission, SAB Biotherapeutics is raising up to $175,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About SAB Biotherapeutics
SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIOs innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma. The science behind the platform originated in 1998, and the company began its first clinical trials in 2017. To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies. The companys lead investigational candidate, SAB-142, is a novel, potentially disease-modifying therapy for type 1 diabetes (T1D). As a potentially redosable human antibody, rather than an insulin or chronic therapy, SAB-142 is being investigated for its ability to delay clinical onset and progression of T1D. .

To learn more about SAB Biotherapeutics, visit https://www.sab.bio/
SAB Biotherapeutics Linkedin Page: https://www.linkedin.com/company/sab-biotherapeutics/

Contact:
Samuel Reich, Chief Executive Officer
305-845-2813
https://www.linkedin.com/in/samuel-reich-5a10963b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.